Chlorpheniramine/hydrocodone/pseudoephedrineAlternative Names: Chlorpheniramine/hydrocodone/pseudoephedrine - Pernix Therapeutics; Chlorpheniramine/pseudoephedrine/hydrocodone; Hydrocodone/chlorpheniramine/pseudoephedrine; Hydrocodone/pseudoephedrine/chlorpheniramine; Pseudoephedrine/chlorpheniramine/hydrocodone; Pseudoephedrine/hydrocodone/chlorpheniramine; ZUTRIPRO
Latest Information Update: 21 Jul 2015
At a glance
- Originator Cypress Pharmaceutical
- Class Antihistamines; Antitussives; Decongestants; Morphinans; Opioid analgesics; Opioid peptides; Propanolamines; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists; Histamine H1 receptor antagonists; Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Common cold; Cough; Nasal congestion